Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Mar 07, 2018 12:00pm
151 Views
Post# 27676008

RE:RE:stock price

RE:RE:stock priceAgreed.

I put many people in to this stock in the past few years.

When I contacted yesterday, they all simply asked if they should sell. They don't really know the story....assume the stock is played out. They could be right in the very short term.

Additionally, all the traders that bought post-halt are likely on their way out.

Thankfully, all those buying today are looking for a higher price in the future.

bfw



SPCEO1 wrote:
Dwizell wrote: I'm very surprise the price is so low today with a lot of volumes. Proft taking ?

We should be north of 10 rignt now, but we may even be red for the day ....


This is completely normal behavior for a stock that just recieved an FDA approval. There are always profit-takers - always. You are rigth that the stock should be north of C$10 right now and it will get there soon enough, but what you are observing right now is just a normal reaction by a certain slice of the shareholder base who are not long term investors. They may come to regret taking profits in the long run, but that is not going to change the fact that they are going to take them anyway. It is just the way it works.

The stock will return to new highs before too much longer. Company management will be out and about talking to insitutional investors andsome are likely to be intrigued by the story and buy. Plus, there are still a lot fo catalysts that will propel the stock in the months ahead. The biggest risk remains a sell-off in the market overall that drags verything down with it, including TH.


Bullboard Posts